FDA Expands Approval of Ceritinib for ALK-Positive Non-Small Cell Lung Cancer

The FDA has approved the targeted therapy ceritinib as an initial treatment for patients with lung cancer that has a mutation in the ALK gene.

Cancer Currents: An NCI Cancer Research Blog